Great news in the new corporate presentation that was released late yesterday and that is that the timeline for the release of R&D data has been stated as Q1, 2021, for xB3-007 (ERT for Gaucher), xB3-004 (IL-1RA), xB3-007 (ERT for Parkinson’s and Lewy Body Dementia) and for xB3-Progranulin for Frontotemporal Dementia/ALS).:
Bioasis - Upcoming R&D Milestones" alt="" />